Vascular Closure Devices

Products used to seal the openings in BLOOD VESSELS from incisions or punctures made during ENDOVASCULAR PROCEDURES.

Also Known As:

Catheterization Closure Devices; Vascular Closure Patches; Catheterization Closure Device; Closure Device, Catheterization; Closure Device, Vascular; Closure Devices, Catheterization; Closure Devices, Vascular; Closure Patches, Vascular; Device, Catheterization Closure; Device, Vascular Closure; Devices, Catheterization Closure; Devices, Vascular Closure; Patches, Vascular Closure; Vascular Closure Device

Networked: 157 relevant articles (11 outcomes, 18 trials/studies)

Relationship Network

Therapy Context: Research Results

Equipment and Supplies
- Surgical Equipment: 77
  - Surgical Fixation Devices: 2
    - Vascular Closure Devices: 157

Experts

1.	Rao, Sunil V: 9 articles (01/2020 - 06/2010)
2.	Mehran, Roxana: 6 articles (08/2021 - 02/2010)
3.	Stone, Gregg W: 4 articles (08/2021 - 02/2010)
4.	Messenger, John C: 4 articles (01/2020 - 06/2010)
5.	Akin, Ibrahim: 3 articles (05/2019 - 05/2017)
6.	Behnes, Michael: 3 articles (05/2019 - 05/2017)
7.	Borggrefe, Martin: 3 articles (05/2019 - 05/2017)
8.	Hoffmann, Ursula: 3 articles (05/2019 - 05/2017)
9.	Mashayekhi, Kambis: 3 articles (05/2019 - 05/2017)
10.	Cohen, David J: 3 articles (01/2019 - 06/2010)

Related Diseases

1.	Hemorrhage 01/01/2017 - "The Mynx device was associated with a significantly greater risk of any vascular complication than were alternative vascular-closure devices (absolute risk, 1.2% vs. 0.8%; relative risk, 1.59; 95% confidence interval [CI], 1.42 to 1.78; P<0.001); there was also a significantly greater risk of access-site bleeding (absolute risk, 0.4% vs. 0.3%; relative risk, 1.34; 95% CI, 1.10 to 1.62; P=0.001) and transfusion (absolute risk, 1.8% vs. 1.5%; relative risk, 1.23; 95% CI, 1.13 to 1.34; P<0.001). " 10/05/2023 - "In participants undergoing coronary procedures by TFA, US guidance decreased the composite outcome of major vascular complications or bleeding and may be especially helpful when using vascular closure devices." 06/28/2011 - "There remains controversy regarding the efficacy, safety, and/or practicality of 3 key bleeding avoidance strategies for cardiac catheterization and coronary intervention: procedural (radial artery approach, safezone arteriotomy), pharmacological (multiple agents), and technological (vascular closure devices) approaches to improved access. " 12/18/2013 - "The ARISE trial will help define the role of a vascular closure device as a bleeding avoidance strategy in patients with NSTEACS. " 01/01/2003 - "The rate of bleeding complications was not significantly different between the two arms of the study, including in those patients who received vascular closure devices. "
2.	ST Elevation Myocardial Infarction 06/01/2011 - "Safety and efficacy of femoral vascular closure devices in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction." 04/01/2016 - "There exists a robust evidence base of superior outcomes in ST-Elevation Myocardial Infarction (STEMI) with radial as opposed to femoral access Benefit of vascular closure devices to decrease femoral access complications remains a matter of contention; the evidence base is largely incomplete Vascular site complications and access site related bleeding may be as much, or more affected by access technique as by method of vascular closure. " 02/15/2015 - "To assess the relationship of femoral vascular closure device (VCD) use to bleeding and ischemic events in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) via different anticoagulation strategies. " 03/30/2016 - "A 77-year-old man with history of ischemic cardiomyopathy with non-ST segment elevation myocardial infarction (NSTEMI) underwent diagnostic cardiac catheterization with deployment of a StarClose SE vascular closure device for hemostasis. " 02/15/2015 - "Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial."
3.	False Aneurysm (Pseudoaneurysm) 10/01/2010 - "In this small study, intravascular sealant and pseudoaneurysms were found frequently after femoral arterial closure with the Mynx vascular closure device." 10/19/2022 - "This case report demonstrates a technique using ultrasonography-guided suture-mediated vascular closure devices without angiography to successfully treat iatrogenic superficial femoral pseudoaneurysm following an unintended hemodialysis catheter insertion. " 10/19/2022 - "Ultrasonography-guided endovascular management of femoral artery pseudoaneurysm after unintended dialysis catheterization with suture-mediated vascular closure devices." 08/01/2021 - "Except for two patients with late pseudoaneurysm on 15th and 23th postoperative day, neither major nor minor vascular complications nor vascular closure device failure according to the Valve Academic Research Consortium-2 definition criteria was observed. " 04/01/2019 - "We describe a case of a successful treatment of refractory iatrogenic femoral artery pseudoaneurysm using Amplatzer vascular plugs following unsuccessful retrograde deployment of an Angio-Seal vascular closure device."
4.	Peripheral Arterial Occlusive Disease 1 09/01/2014 - "In this study, we aimed to evaluate the effectiveness and safety of the Exoseal vascular closure device (Cordis Corporation, Bridgewater, New Jersey, USA) for puncture site closure after antegrade endovascular procedures in peripheral arterial occlusive disease (PAOD) patients. " 04/01/2013 - "To prospectively evaluate safety and efficacy of a novel vascular closure device (Glubran 2 Seal) after peripheral angiography in patients with peripheral arterial occlusive disease (PAOD). " 04/01/2013 - "Efficacy and safety of a novel vascular closure device (Glubran 2 seal) after diagnostic and interventional angiography in patients with peripheral arterial occlusive disease."
5.	Hepatocellular Carcinoma (Hepatoma) 06/01/2014 - "This study was designed to investigate the safety and efficacy of the circumferential clip-based (StarClose) vascular closure device (VCD) in coagulopathic and cirrhotic patients with hepatocellular carcinoma (HCC) after doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). " 06/01/2014 - "Safety and efficacy of a circumferential clip-based vascular closure device in cirrhotic and coagulopathic patients with hepatocellular carcinoma after doxorubicin drug-eluting beads transarterial chemoembolization."

Related Drugs and Biologics

1.	bivalirudin (Angiomax)
2.	Glycoproteins (Glycoprotein)
3.	Doxorubicin (Adriamycin)
4.	glubran 2
5.	tetrachloroisophthalonitrile (Bravo)
6.	Collagen
7.	Heparin (Liquaemin)
8.	Metalloproteases (Metalloproteinases)
9.	Platelet Membrane Glycoprotein IIb
10.	MicroRNAs (MicroRNA)

Related Therapies and Procedures

1.	Percutaneous Coronary Intervention
2.	Surgical Instruments (Clip)
3.	Catheters
4.	Catheter Ablation
5.	Length of Stay